Welcome to Medivizor!

You're browsing our sample library. Feel free to continue browsing. You can also sign up for free to receive medical information specific to your situation.

Posted by on Oct 18, 2018 in Multiple Myeloma | 0 comments

In a nutshell

This paper compared the safety and effectiveness of elotuzumab (Empliciti) plus lenalidomide (Revlimid) and dexamethasone (Decadron) with lenalidomide and dexamethasone in unresponsive multiple myeloma. It was found that elotuzumab plus lenalidomide and dexamethasone was more effective than lenalidomide and dexamethasone alone.

Some background

Many patients respond well to treatment for multiple myeloma. However, some may lose response over time (relapse). Others may not respond at all (refractory). Lenalidomide (Revlimid) and dexamethasone (Decadron) are commonly used together to treat patients with relapsed/refractory multiple myeloma (RRMM). Lenalidomide is an anti-cancer drug. Dexamethasone (Decadron) is a steroid drug. Elotuzumab (Empliciti) is a targeted treatment for MM. This means that it kills only cancer cells. Elotuzumab is more commonly being used in combination with lenalidomide and dexamethasone. It is important to study the safety of this treatment.

Methods & findings

Six hundred and forty-six patients with RRMM were included in this study. Three hundred and nineteen patients received elotuzumab plus lenalidomide and dexamethasone. Three hundred and sixteen patients received lenalidomide and dexamethasone. The safety and effectiveness of the different treatment plans were investigated for 4 years.

Patients treated with elotuzumab plus lenalidomide and dexamethasone were 29% more likely to survive or not experience disease worsening. The greatest benefit of elotuzumab plus lenalidomide and dexamethasone treatment was observed on average after 3.5 years of diagnosis. At this stage, patients were 44% more likely to not experience disease worsening or to survive.

The bottom line

This study found that long-term treatment elotuzumab plus lenalidomide and dexamethasone was safe and effective for patients with RRMM.

The fine print

This study included patients over the age of 18 only. Therefore the results may not apply to younger patients. 

What’s next?

If you have questions about the management of Multiple Myeloma, please consult your doctor.  

Published By :


Date :

Sep 11, 2018

Original Title :

Elotuzumab Plus Lenalidomide and Dexamethasone in Relapsed/Refractory Multiple Myeloma: Extended 4-Year Follow-Up and Analysis of Relative Progression-Free Survival From the Randomized ELOQUENT-2 Trial.

click here to get personalized updates